Skip to main content
OpenTrials
Completed

NCT Number: NCT01912196

Add-On Study of MSI-195 (S-Adenosyl-L-Methionine, SAMe) for Patients With Major Depressive Disorder (MDD)

The purpose of this study is to determine the efficacy and safety of 800 mg MSI-195 in reducing symptoms of depression in Major Depressive Disorder (MDD)patients with inadequate response to current antidepressant therapy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Major Depressive Disorder (MDD) Depressive Disorder Depressive Disorder, Major Mental Disorders Mood Disorders

Age range

21 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 2

Primary location

MSI Investigational Site, Birmingham, Alabama, United States

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Meets the Diagnostic and Statistical Manual of Mental Disorder, 4th Edition, Text Revision (DSM-IV-TR) criteria for Major Depressive Disorder (MDD)
  • A total score of 16 or higher on the Hamilton Rating Scale for Depression- 17 item version (HAM-D17) at the Screening and Baseline Visits, with a score of ≥2 on mood item 1.
  • Have experienced 1-4 prior Major Depressive Episodes. Patients with more than 5 lifetime episodes (including current episode) will require discussion with the medical monitor prior to inclusion.
  • Failed 1-3 treatment regimens in the current depressive episode
  • Received an adequate dose and duration of Antidepressant Therapy (ADT) (on ADT for at least 6 weeks with a stable dose for at least 3 weeks)

Exclusion criteria

  • Failed 4 or more adequate treatment regimens in current episode of depression
  • patient may have a significant risk for suicidal behavior during the course of their participation in the study
  • Intolerance to SAMe; Prior use of MSI-195
  • History of any of the following psychiatric disorders: eating disorder within 6 months; obsessive compulsive disorder, psychotic disorder, bipolar disorder, mental retardation, dementia or other forms of cognitive impairment at any time or alcohol or substance abuse
  • >3X upper limit of normal (ULN) Alkaline Phosphatase, aspartate aminotransferase (AST), alanine aminotransferase (ALT); >1.5X ULN total bilirubin
  • Pregnant or lactating women
  • Any history of seizures, excluding febrile seizures
  • Known positivity for human immunodeficiency virus

Treatment and study plan

MSI-195

Drug

Placebo

Drug

Primary outcomes

  1. Change in the total Hamilton Depression Rating Scale (HAM-D17) between randomization and end of study.

    Time frame: assessed from baseline to week 8 (end of study)

    Based on historical data, the standard deviation is assumed to range between 9 and 12. With a standard effect size of 0.367 a total of at least 120 evaluable patients per group are needed to provide 80% power with a two-sided 5% significance level. HAM-D17 will be derived from the Combined HAM-D28-MADRS Instrument.

Secondary outcomes

  1. change in the total score of the Montgomery-Asberg Depression Rating Scale (MADRS)

    Time frame: collected at baseline, weeks 2, 4, 6, 7 and 8 (end of study)

    for the MADRS, the number and proportion of patients who are responders at the end of the study and the number and proportion of patients who are in remission at the end of the study will be summarized by treatment group, along with the difference and 95% confidence interval for the difference (based on the Wilson Score method).

  2. change in total score of the Clinical Global Impression Improvement Scale (CGI-S)

    Time frame: assessed from baseline, weeks 2, 4, 7 and 8 (end of study)

    the number and proportion of patients who are responders at the end of the study and the number and proportion of patients who are in remission at the end of the study will be summarized by treatment group, along with the difference and 95% confidence interval for the difference (based on the Wilson Score method). Remission is defined as a score of 1 or 2.

  3. change from randomization to each study visit in the total score of the Inventory of Depressive Symptomatology-Self Rated (IDS-SR30)

    Time frame: assessed on baseline visit, Week 2, 4, 6, and 8 (end of study).

    A response is defined as a reduction in the IDS-SR30 score of ≥50% and remission is defined as a score of ≤14.

  4. Adverse events

    Time frame: collected at baseline, weeks 1, 2, 3, 4, 6, 8 and 9 (follow up)

    collected from signing informed consent through 7 days after the last dose of study treatment. Ascertained by qualified clinician.

  5. Columbia Suicide Severity Rating Scale (C-SSRS)

    Time frame: assessed at baseline, weeks 2, 4, 6 and 8 (end of study)

    administered by qualified clinician

Sponsors and collaborators

Lead sponsor

MSI Methylation Sciences, Inc.

Industry

Registry information

Official study title

A Double-Blind, Placebo-Controlled, Randomized Add-On Study of MSI-195 (Methylation Sciences Inc. S-Adenosyl-L-Methionine, SAMe) For Patients With Major Depressive Disorder(MDD) Who Have Had An Inadequate Response to Current Antidepressant Therapy

Important dates

Study start
2013
Primary completion
2015
Study completion
2015
First posted
Jul 31, 2013
Registry last updated
Mar 18, 2016

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.